Endocrinology

Back to articles

Investigational agent reduces fractures in postmenopausal women with osteoporosis

KEY POINT

Abaloparatide, an investigational peptide that selectively activates the parathyroid hormone (PTH)–type 1 receptor, reduced the risk of new vertebral and nonvertebral fractures and increased bone mineral density (BMD) to a greater extent than placebo in postmenopausal women with osteoporosis, according to a study published in JAMA.